Cargando...
CFTR potentiators: From Bench to Bedside
One major breakthrough in cystic fibrosis research in the past decade is the development of drugs that target the root cause of the disease—dysfunctional CFTR protein. One of the compounds, Ivacaftor or Kalydeco, which has been approved for clinical use since 2012, acts by promoting the gating funct...
Guardado en:
| Publicado en: | Curr Opin Pharmacol |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5723237/ https://ncbi.nlm.nih.gov/pubmed/29073476 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.coph.2017.09.015 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|